GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.
Employees: 1,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
500% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 6 (+5) [Q2]
233% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 12
217% more capital invested
Capital invested by funds: $134M [Q1] → $426M (+$291M) [Q2]
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
52% more call options, than puts
Call options by funds: $2.7M | Put options by funds: $1.78M
48% more funds holding
Funds holding: 58 [Q1] → 86 (+28) [Q2]
5.84% more ownership
Funds ownership: 56.44% [Q1] → 62.27% (+5.84%) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Goldman Sachs Matthew Sykes 73% 1-year accuracy 37 / 51 met price target | 4%downside $54 | Neutral Maintained | 16 Oct 2024 |
Wells Fargo Brandon Couillard 40% 1-year accuracy 4 / 10 met price target | 39%downside $34 | Equal-Weight Initiated | 27 Aug 2024 |
TD Cowen Dan Brennan 68% 1-year accuracy 15 / 22 met price target | 11%downside $50 | Buy Maintained | 31 Jul 2024 |
BTIG Mark Massaro 68% 1-year accuracy 19 / 28 met price target | 20%downside $45 | Buy Maintained | 31 Jul 2024 |
Craig-Hallum Bill Bonello 75% 1-year accuracy 3 / 4 met price target | 18%downside $46 | Buy Maintained | 31 Jul 2024 |
Financial journalist opinion
Based on 4 articles about WGS published over the past 30 days